AI assistant
Sending…
Rein Therapeutics, Inc. — Director's Dealing 2019
Apr 17, 2019
34829_dirs_2019-04-17_a4682941-3c91-479b-97a0-08c2545bf86c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AILERON THERAPEUTICS INC (ALRN)
CIK: 0001420565
Period of Report: 2019-04-15
Reporting Person: Gregory Kathryn (SVP, Chief Business Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-04-15 | Stock Option (right to buy) | $1.75 | A | 20000 | Acquired | 2029-04-14 | Common Stock (20000) | Direct |
Footnotes
F1: This option was granted on April 15, 2019. The shares underlying the option are scheduled to vest in equal monthly installments over four years from April 15, 2019.
More from Rein Therapeutics, Inc.
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 4
Regulatory Filings
2026
Apr 28
Annual Report
2026
Apr 27
Annual Report
2026
Mar 26
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Feb 19
Regulatory Filings
2026
Jan 16
Regulatory Filings
2025
Dec 11
Director's Dealing
2025
Nov 18